Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1641 1643 1644
This examiner grants 53% of resolved cases
John Joseph Skoko III handles cases in Art Unit 1612 within Tech Center 1600. With 113 resolved cases, the examiner has an allowance rate of 53.1 percent. This figure suggests a more challenging prosecution environment compared to examiners with higher allowance rates in the same tech center. Practitioners should prepare for rigorous examination given the 53.1 percent allowance rate.
However, the interview lift of 58.2 percent is exceptionally high. This suggests that personal communication is a critical tool for practitioners to improve the odds of allowance significantly above the baseline. The 58.2 percent lift indicates that interviews are highly effective at resolving issues that might otherwise lead to a rejection in Art Unit 1612.
The median days to allowance is 1345, indicating a longer prosecution timeline that may require persistent effort. This duration of 1345 days should be factored into the overall strategy for applications in Tech Center 1600. By analyzing the 113 resolved cases, practitioners can see that while the process is lengthy, interviews offer a strong path to success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18912748 | MATERIALS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 17752892 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER | Non-Final OA | Janssen Biotech, Inc. |
| 17431270 | USE OF PLASMA MEMBRANE PARTICLES, LIPOSOMES, AND EXOSOMES TO ASSAY IMMUNE CELL POTENCY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17598780 | NUCLEAR-DERIVED EXOSOMES AND METHODS OF USE THEREOF | Final Rejection | Board of Regents, The University of Texas System |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | Non-Final OA | Novartis AG |
| 17338569 | COMBINATION THERAPY OF DIFFUSE LARGE B-CELL LYMPHOMA COMPRISING AN ANTI-CD79B IMMUNOCONJUGATES, AN ALKYLATING AGENT AND AN ANTI-CD20 ANTIBODY | Non-Final OA | Hoffmann-La Roche Inc. |
| 18580602 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY DRUG CONJUGATE AND ITS APPLICATION | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18016864 | COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE WITH HER DIMERIZATION INHIBITOR | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 17312084 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH PARP INHIBITOR | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 18012754 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | Non-Final OA | SAPREME TECHNOLOGIES B.V. |
| 18012741 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | Final Rejection | SAPREME TECHNOLOGIES B.V. |
| 17279327 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | Final Rejection | Amod SARNAIK |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy